Abstract
To explore the safety of ropinirole in the treatment of Parkinson's disease(PD). A total of 221 PD patients participated in a multi-center, 12-week randomized, bromocriptine-controlled, double-blind, double-dummy and parallel-group trial.The safety was assessed on the basis of adverse reactions, blood pressure, pulse, laboratory parameters and electrocardiography recordings.The incidence of adverse reaction was 34.9% in ropinirole group and 34.8% in bromocriptine group.And the frequency of adverse reactions had no inter-group statistical significance(χ2=0.000, P=0.995). Ropinirole has an excellent profile of safety in the treatment of Chinese PD patients. Key words: Parkinson's disease; Bromocriptine; Ropinirole
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
